FindTrial
Sign In

An outpatient, randomised, double-blind, placebo controlled, parallel group exploratory study to evaluate safety, tolerability and efficacy of GW679769 in patients with Fibromyalgia syndrome comorbid with depression.

An outpatient, randomised, double-blind, placebo controlled, parallel group exploratory study to evaluate safety, tolerability and efficacy of GW679769 in patients with Fibromyalgia syndrome comorbid with depression.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001010-41-IT
Enrollment
50
Registered
2006-01-03
Start date
2005-07-11
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia MedDRA version: 6.1 Level: PT Classification code 10048439

Interventions

Product Name: NK1-antagonist Product Code: GW679769 Pharmaceutical Form: Tablet Current Sponsor code: GW679769 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-

Sponsors

GLAXO SMITHKLINE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026